Hengrui lands $2.6bn Novo Nordisk deal for experimental weekly oral obesity drug

Novo Nordisk is paying heavily for another shot at extending its lead in obesity treatment, agreeing to a deal worth up to $2.6 billion for Hengrui Pharma’s experimental HRS-1596, a Phase 1-ready GLP-1/GIP dual agonist designed for once-weekly oral dosing. The Danish drugmaker will pay $300 million upfront for rights outside Greater China, with as much as $2.3 billion more tied to development, regulatory and commercial milestones, while Hengrui can also earn royalties on future sales. The deal gives Novo Nordisk another potential oral obesity asset at a time when investors are questioning the depth of its next-generation pipeline and competition from Eli Lilly continues to intensify. HRS-1596 remains extremely early, however, and has not yet produced human efficacy data, meaning Novo Nordisk is effectively paying for the possibility that a weekly pill can eventually combine the convenience of oral treatment with the potency associated with dual incretin therapy.

The transaction also highlights how aggressively Novo Nordisk is using external licensing to supplement internal research. Only days earlier, the company struck another major drug-delivery deal, while management has been trying to convince investors that its pipeline can produce several future multibillion-dollar products as key semaglutide patents approach expiration early in the next decade. Novo Nordisk shares were trading around $38.10 after the announcement and remained down about 21% for the year, suggesting the market is still looking for stronger evidence that new assets can meaningfully extend the company’s obesity leadership.

Novo Nordisk is paying for dosing convenience before HRS-1596 has produced human efficacy data

The central attraction of HRS-1596 is straightforward: Novo Nordisk could eventually have a dual GLP-1/GIP obesity medicine that patients take once a week without an injection. Hengrui has received authorization in China to begin Phase 1 testing in obesity and type 2 diabetes, but the candidate has not yet generated the kind of human weight-loss or glucose-control data that would normally underpin a late-stage investment case.

That makes the economics of the deal important. Novo Nordisk is paying $300 million immediately, but approximately 88% of the headline $2.6 billion value depends on HRS-1596 reaching future milestones. The structure limits the amount of capital at risk if the program encounters problems in Phase 1 or later development while still giving Hengrui substantial upside if the drug ultimately succeeds.

HRS-1596 simultaneously activates GLP-1 and GIP receptors, the same two broad incretin pathways targeted by Eli Lilly’s tirzepatide. Dual agonism has therefore already been commercially and clinically validated as a concept, reducing some of the biological uncertainty around the receptor combination itself.

What remains unproven is whether Hengrui’s molecule can produce sufficiently durable oral exposure to support weekly dosing while maintaining efficacy and tolerability. That could ultimately become the drug’s most important differentiator because the current obesity market largely forces patients to choose between weekly injections and more frequent oral treatment.

A successful weekly tablet could reduce treatment burden, particularly for patients who dislike injections or have difficulty maintaining daily medication routines. Convenience alone will not be enough, however, if competing oral drugs deliver stronger weight reduction, better tolerability or easier manufacturing.

The Hengrui deal adds another layer to Novo Nordisk’s increasingly crowded obesity pipeline

Novo Nordisk is not relying on HRS-1596 as the sole successor to Wegovy. The company is developing a broad portfolio spanning higher-dose semaglutide, CagriSema, oral therapies and next-generation mechanisms intended to improve weight loss, convenience or metabolic outcomes.

That internal competition is becoming strategically important because obesity treatment is evolving rapidly. Drugs no longer compete only on whether they produce clinically meaningful weight loss; manufacturers are increasingly differentiating products through dosing frequency, route of administration, cardiovascular outcomes, tolerability and the amount of lean mass preserved during treatment.

CagriSema remains one of Novo Nordisk’s most advanced next-generation programs. Recent Phase 3 data showed the combination achieved 12.4% weight loss in adults with type 2 diabetes compared with 9.1% for a lower dose of tirzepatide in a head-to-head study, giving Novo Nordisk another potential weapon against Lilly.

Novo Nordisk is also developing oral and injectable zenagamtide and has continued investing in technologies intended to extend drug exposure and improve dosing convenience. HRS-1596 therefore enters a portfolio where multiple candidates could overlap commercially, creating internal competition but also giving management more options if individual programs fail.

The company has said it intends to advance several obesity and diabetes programs through late-stage development by 2030. That ambition reflects the scale of the opportunity but also the urgency created by the eventual expiration of important semaglutide intellectual property.

Once-weekly oral dosing could become a powerful selling point if efficacy remains competitive

Oral obesity treatment is already becoming a major commercial battleground. Novo Nordisk has established experience with oral semaglutide, while multiple rivals are developing small-molecule or peptide-based GLP-1 therapies intended to remove injections from chronic weight-management treatment.

A weekly pill could theoretically improve on daily oral therapy without sacrificing the convenience advantage that tablets hold over injections. That could be especially relevant in primary-care settings, where some patients may prefer a familiar tablet-based regimen rather than a self-administered injectable medicine.

The challenge is pharmacological. Long-acting oral therapies need to achieve reliable absorption and maintain therapeutically useful exposure for several days, something that is substantially more difficult than simply extending the duration of an injected medicine.

Phase 1 development will therefore be critical. Novo Nordisk needs to determine whether HRS-1596 can produce stable exposure across an entire week, whether gastrointestinal side effects remain manageable and whether doses can be escalated high enough to generate clinically meaningful weight loss.

None of those questions has been answered yet. The current deal values the platform potential of HRS-1596 rather than demonstrated human performance, making the $2.6 billion headline figure considerably more speculative than a transaction involving a Phase 2 or Phase 3 obesity asset.

Hengrui gives Novo Nordisk another Chinese pipeline source as global licensing competition accelerates

The deal also reflects a wider change in pharmaceutical business development. Chinese biotechnology and pharmaceutical companies are becoming major sources of globally licensed assets, particularly in oncology and increasingly in metabolic disease.

Hengrui has built a broad research operation across cancer, immunology and cardiometabolic disease and has become increasingly active in partnerships with multinational companies. Novo Nordisk’s latest agreement is another example of a Western drugmaker buying global rights to a Chinese-discovered molecule while allowing the originating company to retain Greater China rights.

The competitive environment is intense. Reuters reported that nearly 250 GLP-1-related candidates are being developed in China, creating a large pool of experimental drugs that global pharmaceutical companies can evaluate for licensing.

That abundance can be advantageous for buyers because it increases the number of mechanisms, formulations and combinations available for external development. It can also push valuations higher when several large pharmaceutical companies compete for assets showing meaningful differentiation.

Hengrui shares rose after the announcement, reflecting the immediate value created by the $300 million upfront payment and the potential milestone stream. Novo Nordisk shares moved only modestly, reinforcing the difference between how investors view the transaction for the smaller licensing partner and for a pharmaceutical company already valued around $170 billion.

Novo Nordisk can afford the deal, but investors want evidence its pipeline can replace future semaglutide growth

The $300 million upfront payment is manageable relative to Novo Nordisk’s financial scale. Adjusted second-quarter sales reached DKK 78.5 billion, while adjusted operating profit was DKK 33.4 billion and rose 11% at constant exchange rates.

Obesity care remained one of the company’s fastest-growing businesses, with adjusted sales rising 16% at constant exchange rates during the quarter. International obesity sales increased particularly strongly, helping offset slower growth in some other regions.

Novo Nordisk also improved its 2026 outlook, expecting adjusted sales and operating profit growth between flat and a 6% decline at constant exchange rates, an improvement from its earlier guidance. Management attributed the change partly to stronger expectations for GLP-1 product sales.

Despite that operating strength, the share price has remained under pressure. Novo Nordisk ADRs fell sharply following its September capital markets presentation and traded near $38 after the Hengrui agreement, well below levels seen earlier in the month.

The disconnect reflects investor concerns about what comes after semaglutide. Wegovy and Ozempic remain enormously important to the company’s valuation, while Lilly has built a formidable competing franchise through tirzepatide and is advancing additional oral and injectable programs of its own.

HRS-1596 does not immediately solve that strategic problem because the molecule is years away from potential commercialization even if development proceeds smoothly. The transaction does, however, increase the number of shots Novo Nordisk has on goal.

That portfolio approach may ultimately matter more than any single licensing agreement. Obesity is becoming too large and scientifically diverse for one molecule to dominate every patient segment indefinitely, making a broad pipeline of oral, injectable, single-receptor and multi-receptor therapies increasingly valuable.

Investors are treating HRS-1596 as a pipeline option rather than a near-term earnings driver

Novo Nordisk shares showed little enthusiasm following the announcement, with the U.S.-listed stock trading around $38.10 and down roughly 21% year to date. BMO Capital maintained a Market Perform rating and a $47 price target, indicating that the licensing deal did not materially change its broader view of the company.

That muted reaction is understandable given the development stage. HRS-1596 cannot contribute revenue until it completes multiple years of clinical testing and regulatory review, and the probability of success for any Phase 1-ready medicine remains substantially lower than for a late-stage asset.

Investors are therefore likely to focus first on whether the drug produces competitive Phase 1 pharmacokinetics and early weight-loss signals. If weekly oral exposure proves feasible and efficacy begins approaching established injectable therapies, the asset could become considerably more important to Novo Nordisk’s valuation. If it fails, Novo Nordisk’s initial loss is largely limited to the $300 million upfront payment and development expenditure rather than the full $2.6 billion headline value.

The agreement ultimately gives Novo Nordisk another potentially differentiated obesity therapy without forcing the company to commit the entire acquisition price upfront. For Hengrui, it converts an early-stage Chinese program into a globally funded development opportunity. For Novo Nordisk investors, HRS-1596 is best viewed as another long-term pipeline option in a market where the company increasingly needs multiple successful successors to maintain its leadership.

Key takeaways from Novo Nordisk’s $2.6 billion HRS-1596 obesity deal

• Novo Nordisk is paying Hengrui Pharma $300 million upfront for global HRS-1596 rights outside Greater China, with total potential payments reaching $2.6 billion.
• HRS-1596 is a Phase 1-ready GLP-1/GIP dual agonist designed for once-weekly oral dosing in obesity and type 2 diabetes.
• The candidate has not yet produced human efficacy data, making the transaction a relatively early and high-risk pipeline investment.
• Most of the deal value is milestone-based, limiting Novo Nordisk’s immediate financial exposure if development fails.
• A successful weekly pill could differentiate HRS-1596 from daily oral therapies and weekly injectable incretin drugs.
• The asset joins an already broad Novo Nordisk obesity pipeline that includes CagriSema, semaglutide and other next-generation programs.
• Novo Nordisk reported DKK 78.5 billion in adjusted second-quarter sales, giving it substantial capacity to fund external licensing.
• Shares remain under pressure despite improving GLP-1 sales expectations as investors focus on competition and the company’s post-semaglutide pipeline.
• Phase 1 pharmacokinetic, safety and early efficacy data will be the first meaningful test of whether HRS-1596 can justify the deal’s long-term value.